INO - Inovio Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Plymouth Meeting,
United States
Type: Equity
INO price evolution
INO
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.31 | $18.8 | $52.71 | $28.24 |
| Short term investments | $130.98 | $148.67 | $142.21 | $195.51 |
| Net receivables | $2.41 | $2.14 | $5.12 | $5.04 |
| Inventory | ||||
| Total current assets | $153.11 | $174.77 | $203.28 | $233.9 |
| Long term investments | $2.78 | $2.99 | $2.78 | $2.62 |
| Property, plant & equipment | $14.45 | $14.73 | $15.79 | $16.85 |
| Goodwill & intangible assets | $10.51 | $12.56 | ||
| Total noncurrent assets | $17.84 | $18.33 | $29.75 | $32.69 |
| Total investments | $133.76 | $151.66 | $144.99 | $198.14 |
| Total assets | $170.95 | $193.1 | $233.04 | $266.58 |
| Current liabilities | ||||
| Accounts payable | $20.92 | $16.27 | $22.95 | $26.17 |
| Deferred revenue | ||||
| Short long term debt | $19.18 | $18.61 | $19.06 | $18.97 |
| Total current liabilities | $42.57 | $43.71 | $51.93 | $55.15 |
| Long term debt | $11.03 | $11.19 | $11.7 | $12.19 |
| Total noncurrent liabilities | $11.03 | $11.23 | $11.73 | $12.22 |
| Total debt | $30.21 | $29.8 | $30.76 | $31.16 |
| Total liabilities | $53.6 | $54.94 | $63.67 | $67.37 |
| Shareholders' equity | ||||
| Retained earnings | -$1622.97 | -$1597.96 | -$1564.03 | -$1528.5 |
| Other shareholder equity | -$0.66 | -$0.75 | -$0.69 | -$0.58 |
| Total shareholder equity | $117.35 | $138.16 | $169.37 | $199.21 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.31 | $46.33 | $71.14 | $250.73 |
| Short term investments | $130.98 | $206.67 | $330.17 | $160.91 |
| Net receivables | $2.41 | $11.74 | $8.03 | $19.06 |
| Inventory | ||||
| Total current assets | $153.11 | $315.24 | $448.44 | $471.17 |
| Long term investments | $2.78 | $2.01 | $3.91 | $4.89 |
| Property, plant & equipment | $14.45 | $17.96 | $29.02 | $24.09 |
| Goodwill & intangible assets | $12.64 | $13.14 | $13.66 | |
| Total noncurrent assets | $17.84 | $33.29 | $47.5 | $68.6 |
| Total investments | $133.76 | $208.68 | $334.08 | $165.81 |
| Total assets | $170.95 | $348.53 | $495.94 | $539.77 |
| Current liabilities | ||||
| Accounts payable | $20.92 | $65.08 | $48.19 | $21.85 |
| Deferred revenue | $0.09 | $0.13 | ||
| Short long term debt | $19.18 | $2.8 | $2.6 | $2.33 |
| Total current liabilities | $42.57 | $96.87 | $65.74 | $41.71 |
| Long term debt | $11.03 | $16.61 | $30.42 | $36.72 |
| Total noncurrent liabilities | $11.03 | $29.3 | $30.53 | $36.93 |
| Total debt | $30.21 | $32.07 | $33.02 | $39.05 |
| Total liabilities | $53.6 | $126.17 | $96.27 | $78.63 |
| Shareholders' equity | ||||
| Retained earnings | -$1622.97 | -$1487.85 | -$1209.86 | -$906.2 |
| Other shareholder equity | -$0.66 | -$0.7 | -$0.28 | -$0.26 |
| Total shareholder equity | $117.35 | $222.36 | $399.67 | $461.14 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.1 | $0.39 | $0.23 | $0.11 |
| Cost of revenue | ||||
| Gross Profit | $0.1 | $0.39 | $0.23 | $0.11 |
| Operating activities | ||||
| Research & development | $17.25 | $15.5 | $23.74 | $30.18 |
| Selling, general & administrative | $10.24 | $9.93 | $13.52 | $13.89 |
| Total operating expenses | $27.5 | $35.94 | $37.27 | $44.07 |
| Operating income | -$27.39 | -$35.55 | -$37.04 | -$43.95 |
| Income from continuing operations | ||||
| EBIT | -$24.72 | -$33.62 | -$35.22 | -$40.34 |
| Income tax expense | ||||
| Interest expense | $0.28 | $0.31 | $0.31 | $0.31 |
| Net income | ||||
| Net income | -$25 | -$33.93 | -$35.53 | -$40.65 |
| Income (for common shares) | -$25 | -$33.93 | -$35.53 | -$40.65 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.83 | $10.26 | $1.77 | $7.41 |
| Cost of revenue | ||||
| Gross Profit | $0.83 | $10.26 | $1.77 | $7.41 |
| Operating activities | ||||
| Research & development | $86.68 | $187.65 | $249.24 | $94.25 |
| Selling, general & administrative | $47.58 | $90.19 | $53.75 | $37.25 |
| Total operating expenses | $144.77 | $277.84 | $302.99 | $131.49 |
| Operating income | -$143.94 | -$267.57 | -$301.22 | -$124.08 |
| Income from continuing operations | ||||
| EBIT | -$133.89 | -$278.56 | -$301.72 | -$157.71 |
| Income tax expense | $4.58 | |||
| Interest expense | $1.22 | $1.25 | $1.94 | $8.7 |
| Net income | ||||
| Net income | -$135.12 | -$279.82 | -$303.66 | -$166.41 |
| Income (for common shares) | -$135.12 | -$279.82 | -$303.66 | -$166.41 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$25 | -$33.93 | -$35.53 | -$40.65 |
| Operating activities | ||||
| Depreciation | $0.18 | $1.03 | $1.14 | $1.15 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.27 | $2.08 | $2.92 | $3.81 |
| Total cash flows from operations | -$26.28 | -$29.11 | -$32.31 | -$36.66 |
| Investing activities | ||||
| Capital expenditures | $0.15 | -$0.02 | $5.77 | |
| Investments | $19.8 | -$5.49 | $53.93 | $13.23 |
| Total cash flows from investing | $19.94 | -$5.49 | $53.91 | $19 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.84 | $0.71 | $2.92 | |
| Net borrowings | ||||
| Total cash flows from financing | $1.84 | $0.7 | $2.88 | -$0.42 |
| Effect of exchange rate | $0 | -$0 | -$0 | -$0 |
| Change in cash and equivalents | -$4.49 | -$33.91 | $24.47 | -$18.09 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$135.12 | -$279.82 | -$303.66 | -$166.41 |
| Operating activities | ||||
| Depreciation | $3.5 | $5.5 | $4.73 | $4.63 |
| Business acquisitions & disposals | -$2 | $35.95 | ||
| Stock-based compensation | $11.07 | $22.56 | $26.34 | $15.65 |
| Total cash flows from operations | -$124.37 | -$216.22 | -$215.71 | -$177.98 |
| Investing activities | ||||
| Capital expenditures | $5.9 | -$0.97 | -$1.23 | -$1.52 |
| Investments | $81.46 | $112.56 | -$174.11 | -$93.23 |
| Total cash flows from investing | $87.36 | $109.59 | -$175.34 | -$58.8 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.46 | $83.24 | $216.11 | $454.49 |
| Net borrowings | $0.17 | |||
| Total cash flows from financing | $5 | $81.84 | $211.5 | $465.28 |
| Effect of exchange rate | -$0 | -$0.03 | -$0.03 | $0.03 |
| Change in cash and equivalents | -$32.02 | -$24.81 | -$179.58 | $228.53 |
News
Fundamentals
| Market cap | $220.64M |
|---|---|
| Enterprise value | $236.54M |
| Shares outstanding | 22.79M |
| Revenue | $832.01K |
|---|---|
| EBITDA | -$130.39M |
| EBIT | -$133.89M |
| Net Income | -$135.12M |
| Revenue Q/Q | -17.66% |
| Revenue Y/Y | -91.89% |
| P/E ratio | -1.63 |
|---|---|
| EV/Sales | 284.29 |
| EV/EBITDA | -1.81 |
| EV/EBIT | -1.77 |
| P/S ratio | 265.19 |
| P/B ratio | 1.87 |
| Book/Share | 5.18 |
| Cash/Share | 0.63 |
| EPS | -$5.93 |
|---|---|
| ROA | -62.58% |
| ROE | -86.60% |
| Debt/Equity | 0.46 |
|---|---|
| Net debt/EBITDA | -0.30 |
| Current ratio | 3.60 |
| Quick ratio | 3.60 |